One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration

Imoro Zeba Braimah, Komal Agarwal, Ahmad Mansour, Jay Chhablani

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)

Abstract

Aim To evaluate 12-month outcome of intravitreal ziv-aflibercept (IVZ) therapy in eyes with neovascular age-related macular degeneration (nAMD) that are non-responsive to bevacizumab and ranibizumab. Methods This retrospective study included 16 eyes (14 patients) with nAMD who were on prior treatment with bevacizumab and ranibizumab and were treated with as-needed IVZ (1.25 mg/0.05 mL) for 12 months. The primary outcome measure was the mean change in best corrected visual acuity (BCVA) and secondary outcome measures included mean change in central macular thickness (CMT), retinal pigment epithelial detachment (RPED) heights, longest treatment free interval, presence of subretinal fluid (SRF) and intraretinal fluid (IRF) and adverse events. Results There was no change in the mean logarithm of minimum angle of resolution (logMAR) BCVA at baseline and following treatment with IVZ therapy (p=0.978). The mean number of IVZ injections during 12 months was 5.9±3.3, and the mean number of antivascular endothelial growth factors (VEGFs) injections prior to switching to IVZ was 8.4±4.7. The mean treatment free interval was longer during IVZ therapy (114.4±67.1 days) compared with 76.3±54.6 days before IVZ therapy (p=0.03). Five (31.25%) eyes had visual gains of at least 0.1 logMAR, 3 (18.75%) eyes had stable BCVA (within 0.1 logMAR) and 8 (50%) eyes had BCVA decline of at least 0.1 logMAR. There was no significant difference in the mean CMT, RPED heights and presence of IRF and SRF at 12 months compared with baseline. No adverse events were noted. Conclusion IVZ increased the treatment free interval in non-responders but no significant change in visual and anatomic outcomes.

Original languageEnglish
Pages (from-to)91-96
Number of pages6
JournalBritish Journal of Ophthalmology
Volume102
Issue number1
DOIs
Publication statusPublished - 1 Jan 2018

Keywords

  • AMD
  • Aflibercept
  • Anti-VEGF
  • Bevacizumab
  • Choroidal neovascularization
  • Ranibizumab
  • Ziv-aflibercept

Fingerprint

Dive into the research topics of 'One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration'. Together they form a unique fingerprint.

Cite this